Table 3 The effects of iTBS on SANS and glucometabolic parameters in patients with schizophrenia.
From: Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia
Pre-treatment | Post-treatment | Repeated measure test within group (P value) | ∆ of pre- and post-treatment | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
iTBS | Control | iTBS | Control | iTBS | Control | iTBS | Control | Mean difference (95%CI) | Cohen d (95%CI) | P value | |
SANS | 68.32 (11.84) | 66.38 (7.12) | 55 (16.76) | 65.79 (8.91) | 0.001 | 0.077 | −13.32 (15.29) | -0.59 (5.94) | −12.73 (−18.85 to −6.62) | 1.11 (0.54–1.66) | <0.001* |
FG (mmol/L) | 5.52 (0.84) | 5.19 (0.79) | 5.16 (1.01) | 5.37 (1.00) | 0.181 | 0.720 | −0.36 (0.78) | 0.18 (0.57) | −0.54 (−0.9 to −0.18) | 0.79 (0.25–1.33) | 0.004* |
FI (mU/L) | 13.28 (7.55) | 12.40 (6.86) | 9.63 (4.84) | 13.99 (6.35) | 0.063 | 0.231 | −3.65 (7.11) | 1.59 (8.07) | −5.24 (−9.28 to −1.19) | 0.69 (0.15–1.22) | 0.012* |
HOMA-IR | 3.34 (2.14) | 2.91 (1.89) | 2.15 (0.99) | 3.33 (1.56) | 0.046 | 0.211 | −1.19 (1.97) | 0.41 (2.07) | −1.60 (−2.68 to −0.53) | 0.79 (0.25–1.33) | 0.004* |
